Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dornase alfa + cisplatin
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Dornase alfa + cisplatin is an investigational combination therapy being developed by the National Cancer Institute in Slovakia for the treatment of relapsed or refractory germ cell tumors. Dornase alfa is a recombinant human deoxyribonuclease I (rhDNase I) that degrades extracellular DNA, including neutrophil extracellular traps (NETs), which have been implicated in promoting chemotherapy resistance and poor prognosis in germ cell tumors. Cisplatin is a standard platinum-based chemotherapy agent that induces cell death by forming DNA adducts and crosslinks. The combination aims to restore cisplatin sensitivity by degrading extracellular DNA in the tumor microenvironment, thereby enhancing the efficacy of the chemotherapy. This approach is currently being evaluated in a Phase II clinical trial (NCT07121322).
- Other names
- dornase alfa and cisplatinrhDNase I and cisplatin
02
Targets
eDNA (Extracellular DNA)
Beyond the preview
Go deeper on dornase alfa + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dornase alfa + cisplatin.